

동안신경마비가 동반된 거대세포 동맥염 환자의 치료 경험 중례보고

아주대학교 의과대학 마취통증의학교실 신경통증클리닉

류 영 빈 · 한 경 림 · 김 찬

A Case Report of Giant Cell Arteritis Combined with Oculomotor Nerve Palsy

Young Bin Ryu, M.D., Kyung Ream Han, M.D., and Chan Kim, M.D.

Neuro-pain Clinic, Department of Anesthesiology and Pain Medicine, College of Medicine, Ajou University, Suwon, Korea

Giant cell arteritis, which is also referred to as temporal arteritis, is defined as a systemic vasculitis in individuals over 50 years of age. Here, we report a case of giant cell arteritis combined with oculomotor nerve palsy. An 81-year old female patient experienced a headache for 10 days in her left temporoparietal area, that was characterized by a continuous dull ache and heaviness with intermittent shooting and lancinating pain. Her symptoms persisted in spite of receiving strong analgesics in another hospital. Upon physical examination, she was found to have marked tenderness over the left temporal area, especially along the path of the temporal artery as well as limitation of adduction, supraduction and infraduction of the left eyeball. At the time of admission, her erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were 52 mm/hr and 3.94 mg/dl. In addition her brain MRI revealed no specific findings. Giant cell arteritis was suspected based on the clinical symptoms and signs as well as the elevated ESR and CRP. Oral steroid therapy started was started with an initial dose of 40 mg of prednisolone per day that was gradually tapered to 5 mg a day for 2 weeks. Her headache subsided one day after the steroid therapy and oculomotor nerve palsy was markedly improved after 2 weeks of the therapy. After 2 months she had recovered completely from her symptoms. (Korean J Pain 2007; 20: 255-257)

Key Words: giant cell arteritis, oculomotor nerve palsy, steroid therapy.

		Group 1		Group 2	
81	10	10	10	60	69
(VAS) 80/100		10	80	100,000	844
	visual analogue score			2	American college of
				(1) 50	Rheumatology
				(2)	
				(3)	
				(4)	(≥
				50 mm/h) (5)	(
)
				3	
				4,11,13)	
mm/h, C-reactive protein 3.94 mg/dl		52			
		50			
	C-reactive protein				CRP
	0.3% mepivacaine 3 ml				2
	VAS 40/100				
80/100		1	VAS		
	Prednisolone 40 mg	2	5		
mg					
		2		15	40%
	prednisolone 5 mg	14			
CRP	16 mm/h, 0.09 mg/dl				30%
10					
		2		15%	
	CRP			3)	

ESR,

CRP

2



1 mg/kg/d

.^{1,4)}

prednisolone

⁸⁾

40 mg

, ESR, CRP

ESR, CRP

3

⁸⁾

6 9

prednisolone 10 mg , 1

5 7.5 mg

ESR CRP

ESR CRP

2

⁵⁾

1. Carroll SC, Gaskin BJ, Danesh-Meyer HV: Giant cell arteritis. *Clin Experiment Ophthalmol* 2006; 34: 159-73.
2. Paraskevas KI, Boumpas DT, Vrentzos GE, Mikhailidis DP: Oral and ocular/orbital manifestations of temporal arteritis: a disease with deceptive clinical symptoms and devastating consequences. *Clin Rheumatol* 2007; 26: 1044-8.
3. Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, Garcia-Porrua C, Sanchez-Andrade A, Paz-Carreira J, et al: Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. *Medicine (Baltimore)* 2005; 84: 277-90.
4. Bhatti MT, Tabandeh H: Giant cell arteritis: diagnosis and management. *Curr Opin Ophthalmol* 2001; 12: 393-9.
5. Rahman W, Rahman FZ: Giant cell (temporal) arteritis: an overview and update. *Surv Ophthalmol* 2005; 50: 415-28.
6. Ferraccioli GF, Di Poi E, Damato R: Steroid sparing therapeutic approaches to polymyalgia rheumatica -giant cell arteritis. State of the art and perspectives. *Clin Exp Rheumatol* 2000; 18: 58-60.
7. Drehmer TJ, Khanna D, Markert RJ, Hawkins RA: Diagnostic and management trends of giant cell arteritis: a physician survey. *J Rheumatol* 2005; 32: 1283-9.
8. Hayreh SS, Zimmerman B: Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. *Ophthalmology* 2003; 110: 1204-15.
9. Lincoff NS, Erlich PD, Brass LS: Thrombocytosis in temporal arteritis rising platelet counts: a red flag for giant cell arteritis. *J Neuroophthalmol* 2000; 20: 67-72.
10. Hayreh SS, Zimmerman B: Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. *Ophthalmologica* 2003; 217: 239-59.
11. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al: The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. *Arthritis Rheum* 1990; 33: 1122-8.
12. Gurwood AS, Malloy KA: Giant cell arteritis. *Clin Exp Optom* 2002; 85: 19-26.
13. Park SY, Han KR, Cho WD, Lee SH, Kim C: A case report of temporal arteritis. *Korean J Anesthesiol* 2003; 44: 138-41.